Table 1.

Sensitivity of FNA cytology, NCB, and combined FNA/NCB in 129 malignant cases and 12 benign cases

	Diagnostic sensitivity (%)
Biopsy site	FNA	NCB	Combined
Malignant
Liver
Metastatic malignancy (n=87)	75 (86.2)	71 (82.8)	77 (88.5)
Hepatocellular carcinoma (n=9)	9 (100)	8 (88.9)	9 (100)
Pancreas (n=14)	11 (78.6)	10 (71.4)	13 (92.9)
Kidney (n=5)	5 (100)	3 (60)	5 (100)
Adrenal (n=2)	0 (0)	1 (50)	1 (50)
Retroperitoneum (n=3)	2 (66.7)	3 (100)	3 (100)
Abdomen/pelvis, NOS (n=9)	9 (100)	8 (88.9)	9 (100)
Total (n=129)	111 (86)	104 (80.6)	117 (90.7)
Benign
Liver (n=9)	9 (100)	8 (88.9)	9 (100)
Pancreas (n=3)	2 (66.7)	1 (33.3)	2 (66.7)
Total (n=12)	11 (91.7)	9 (75)	11 (91.7)

FNA, fine needle aspiration; NCB, needle core biopsy, NOS, not otherwise specified.